Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E Adjustments
Ratios

Coya Therapeutics (COYA) EBIAT (2022 - 2025)

Coya Therapeutics' EBIAT history spans 4 years, with the latest figure at -$2.1 million for Q3 2025.

  • For Q3 2025, EBIAT rose 47.39% year-over-year to -$2.1 million; the TTM value through Sep 2025 reached -$18.4 million, down 72.29%, while the annual FY2024 figure was -$14.9 million, 86.29% down from the prior year.
  • EBIAT for Q3 2025 was -$2.1 million at Coya Therapeutics, up from -$6.1 million in the prior quarter.
  • Across five years, EBIAT topped out at $1.3 million in Q4 2023 and bottomed at -$7.3 million in Q1 2025.
  • The 4-year median for EBIAT is -$3.1 million (2022), against an average of -$3.4 million.
  • The largest annual shift saw EBIAT soared 140.74% in 2023 before it tumbled 330.32% in 2024.
  • A 4-year view of EBIAT shows it stood at -$3.1 million in 2022, then soared by 140.74% to $1.3 million in 2023, then crashed by 330.32% to -$2.9 million in 2024, then increased by 27.44% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's EBIAT are -$2.1 million (Q3 2025), -$6.1 million (Q2 2025), and -$7.3 million (Q1 2025).